Well, the board of CXS has just handed us shareholders a big (expletive deleted) sandwich.
In effect they have told us: * We're not competent enough to get the drug through the FDA approval process and on to commercialisation. * We're too dumb or lazy to seek a competetive bid from a myriad of hungry pharma companies out there, looking to bolster their product range. * We give up.
What a pathetic effort.
CXS Price at posting:
67.5¢ Sentiment: None Disclosure: Held